EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mefunidone treats pulmonary fibrosis by targeting SDH to regulate fibro-promoting macrophages

Xiangyu Zhang, Yijun He, Lingzhi Long, Guoliang Jiang, Tingting Yao, Xiaoyun Cheng, Zhangzhe Peng, Gaoyun Hu, Lijian Tao, Jie Meng

International Immunopharmacology · 2025-07 · 160 · 114971

DOI: 10.1016/j.intimp.2025.114971 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025-07. Verfasst von Xiangyu Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Third Xiangya Hospital, Central South University, Changsha, China; Central South University, Chan…. Hauptthemen laut MEDLINE: Macrophages, Succinate Dehydrogenase, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Pulmonary fibrosis, a pathological process where the extracellular matrix overly deposits in lung tissue because of various pathogenic factors, leads to lung structure damage and function decline. Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and high mortality, lacking effective drug treatments. Mefunidone (MFD), a new small-molecule compound, showed therapeutic effects on it in previous studies, but its specific molecular target is unknown. This study aims to clarify MFD's target and its potential mechanism. By exploring this, we hope to offer new insights and potential solutions for treating IPF and improving patients' outcomes. METHODS: Mice with pulmonary fibrosis induced by bleomycin (BLM) were used as experimental models. MFD was administered by gavage. The changes in inflammation and fibrosis were evaluated through histopathological examinations. Subsequently, single-cell sequencing technology was used to explore how MFD affects the phenotype of pro-fibrotic macrophages, and verification was carried out in vitro to prove that MFD treats pulmonary fibrosis by influencing the phenotype of pro-fibrotic macrophages. RESULT: MFD can inhibit the generation of succinate by binding and inhibiting the activity of succinate dehydrogenase (SDH). MFD can also inhibit the transformation of MMP12+CCL2+ profibrotic macrophages in the BLM pulmonary fibrosis model. Treatment with succinate can induce the transformation of macrophages into MMP12+CCL2+ profibrotic macrophages, and this induction depends on the succinate-specific receptor GPR91. CONCLUSION: Our research results have revealed for the first time that MFD can treat pulmonary fibrosis by targeting SDH and regulating the transformation of MMP12+CCL2+ profibrotic macrophages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MacrophagesSuccinate DehydrogenasePulmonary FibrosisIdiopathic Pulmonary FibrosisPyridonesAnimalsBleomycinMiceMice, Inbred C57BLMaleDisease Models, AnimalLungHumansMatrix Metalloproteinase 12

Stichwörter der Autor:innen

Cell transformationDrug targetsMacrophagePulmonary fibrosis

Substanzen

BleomycinSuccinate DehydrogenasePyridonesMatrix Metalloproteinase 12

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Third Xiangya Hospital, Central South University, Changsha, China; Central South University, Changsha, China.
  • Hunan Key Laboratory of Organ Fibrosis, Central South University, Changsha, China; Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
  • Central South University, Changsha, China.
  • Department of Pulmonary and Critical Care Medicine, Third Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratory of Organ Fibrosis, Central South University, Changsha, China; Central South Uni…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, X., He, Y., Long, L., Jiang, G., Yao, T., Cheng, X., Peng, Z., Hu, G., Tao, L., & Meng, J. (2025). Mefunidone treats pulmonary fibrosis by targeting SDH to regulate fibro-promoting macrophages. International Immunopharmacology, 160, 114971. https://doi.org/10.1016/j.intimp.2025.114971

Vancouver

Zhang X, He Y, Long L, Jiang G, Yao T, Cheng X, et al. Mefunidone treats pulmonary fibrosis by targeting SDH to regulate fibro-promoting macrophages. International Immunopharmacology. 2025;160:114971. doi:10.1016/j.intimp.2025.114971

BibTeX
@article{Zhang2025,
  author = {Zhang, Xiangyu and He, Yijun and Long, Lingzhi and Jiang, Guoliang and Yao, Tingting and Cheng, Xiaoyun and Peng, Zhangzhe and Hu, Gaoyun and Tao, Lijian and Meng, Jie},
  title = {Mefunidone treats pulmonary fibrosis by targeting SDH to regulate fibro-promoting macrophages},
  journal = {International Immunopharmacology},
  year = {2025},
  volume = {160},
  pages = {114971},
  doi = {10.1016/j.intimp.2025.114971}
}
Kostenlos starten →